150 related articles for article (PubMed ID: 3896044)
21. [Hemorheologic and clinical in vitro and in vivo studies of the effectiveness of isovolemic hemodilution using Gelafusal and Infukoll M40 in patients with peripheral arterial occlusive disease].
Pöhlmann G; Braumann A; Grohmann G
Vasa Suppl; 1991; 32():342-4. PubMed ID: 1722914
[No Abstract] [Full Text] [Related]
22. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
[TBL] [Abstract][Full Text] [Related]
23. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
Maksimović ZV
Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
[TBL] [Abstract][Full Text] [Related]
24. Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease.
Lee BY; Berkowitz P; Savitsky JP; May GS; Brobst J; McCann WJ
Clin Cardiol; 1985 Mar; 8(3):161-5. PubMed ID: 3978888
[TBL] [Abstract][Full Text] [Related]
25. [Bag plasmapheresis in patients with stage IIb peripheral arterial occlusive disease].
Kiesewetter H; Blume J; Jung F; Gerhards M; Spitzer S; Leipnitz G; Wenzel E
Klin Wochenschr; 1988 Apr; 66(7):284-91. PubMed ID: 2453705
[TBL] [Abstract][Full Text] [Related]
26. [Effects of pentoxifylline on blood viscosity and peripheral hemodynamics in patients with peripheral occlusive arteriopathies].
Guerrini M; Pecchi S; Rossi C; Cappelli R; Pieragalli D; Acciavatti A
Ric Clin Lab; 1981; 11 Suppl 1():265-79. PubMed ID: 7188114
[No Abstract] [Full Text] [Related]
27. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease.
Ehrly AM
Angiology; 1976 Mar; 27(3):188-96. PubMed ID: 1078314
[TBL] [Abstract][Full Text] [Related]
28. [A therapeutic comparison between hemodilution and pentoxifylline in arterial obstructive disease. An objective assessment by quantitative Doppler sonography].
Triebe G; Münnich U; Liebold F
Dtsch Med Wochenschr; 1992 Apr; 117(14):523-30. PubMed ID: 1555499
[TBL] [Abstract][Full Text] [Related]
29. [Effect of an infusion of piribedil in normal subjects and in patients with peripheral obliterating arterial disease on the blood flow of the lower limbs and on blood, plasma and serum viscosity].
Forconi S; Guerrini M; Agnusdei D; Di Perri T
Minerva Med; 1976 May; 67(25):1671-80. PubMed ID: 934519
[No Abstract] [Full Text] [Related]
30. Pentoxifylline -- a biomedical profile.
Müller R
J Med; 1979; 10(5):307-29. PubMed ID: 393789
[TBL] [Abstract][Full Text] [Related]
31. Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline.
Rudofsky G; Haussler KF; Künkel HP; Schneider-May H; Spengel F; Symann O; Werner HJ
Angiology; 1989 Jul; 40(7):639-49. PubMed ID: 2662830
[TBL] [Abstract][Full Text] [Related]
32. Blood fluidity and coagulation phenomena in chronic arterial occlusive disease.
Angelkort B; Boateng K; Maurin N
J Int Med Res; 1980; 8(3):242-6. PubMed ID: 7389992
[TBL] [Abstract][Full Text] [Related]
33. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
Allegra C; Antignani PL; Schachter I; Koverech A; Messano M; Virmani A
Ann Vasc Surg; 2008; 22(4):552-8. PubMed ID: 18502605
[TBL] [Abstract][Full Text] [Related]
34. [Walk training and drug therapy in peripheral arterial occlusive disease. A randomized, prospective, placebo-controlled double-blind study].
Kiesewetter H; Blume J; Jung F; Gerhards M; Leipnitz G
Dtsch Med Wochenschr; 1987 May; 112(22):873-8. PubMed ID: 3556133
[TBL] [Abstract][Full Text] [Related]
35. Haemorheological effects of fructose-1,6-diphosphate in patients with lower extremity ischaemia.
Cacioli D; Clivati A; Pelosi P; Megevand J; Galeone M
Curr Med Res Opin; 1988; 10(10):668-74. PubMed ID: 3371082
[TBL] [Abstract][Full Text] [Related]
36. [Arterial occlusive disease: reducing blood viscosity through drugs].
Gnauen H
Med Klin; 1981 Feb; 76(5):144-6. PubMed ID: 7219342
[No Abstract] [Full Text] [Related]
37. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb.
Kiesewetter H; Blume J; Jung F; Spitzer S; Wenzel E
J Intern Med; 1990 Feb; 227(2):107-14. PubMed ID: 1688914
[TBL] [Abstract][Full Text] [Related]
38. [Hypervolemic hemodilution with medium molecular-weight hydroxyethyl starch: effect of duration of administration on viscoelasticity of blood in IIa and IIb peripheral arterial occlusive disease].
Költringer P; Langsteger W; Lind P; Klima G; Pierer G; Reisecker F; Eber O
Acta Med Austriaca; 1991; 18 Suppl 1():45-7. PubMed ID: 1719731
[TBL] [Abstract][Full Text] [Related]
39. [Hemorheologic therapy applications in coronary heart disease].
Leschke M; Motz W; Strauer BE
Wien Med Wochenschr; 1986; 136 Spec No():17-24. PubMed ID: 3825169
[TBL] [Abstract][Full Text] [Related]
40. [Hemodilution in peripheral arterial occlusive disease--study comparing 3 different variants of hemodilution].
Weidinger P; Bilek M; Tekusch A
Vasa Suppl; 1990; 30():137-8. PubMed ID: 2075564
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
